Enliven Therapeutics (ELVN) Capital Expenditures Growth (3y) (2022 - 2025)
Enliven Therapeutics (ELVN) Capital Expenditures Growth (3y) (2022 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 16.27% |
| 10 | Enliven Therapeutics | 3.39 Bn | 2.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -27.47% |
| Jun 30, 2025 | -22.88% |
| Mar 31, 2025 | -53.11% |
| Mar 31, 2024 | 18.56% |
| Dec 31, 2023 | 76.52% |
| Jun 30, 2023 | 132.52% |
| Mar 31, 2023 | 27.38% |
| Sep 30, 2022 | -38.09% |